The Memphis Business Group on Health (MBGH) is pleased to make this forum, including all web pages and web sites accessed from this page, available to Web Site users and others. However, the MBGH does not render legal or consultation services, and legal counsel must be consulted to determine any material’s applicability to any specific situation. MBGH cannot warrant or control the quality, accuracy, or validity of the information posted here. Comments posted on this blog are the sole responsibility of their writers. Use of such information is at the risk of the accessing user and the accessing user assumes all liabilities that may result from such use.




More Evidence Supports Value-Based Insurance Design

From the Center for Value-Based Insurance Design and National Business Coalition on Health: 

More evidence is piling up that clinically nuanced copayment reductions lead to improvements in medication adherence. Click here to read more background on how clinical nuance is used in benefit design.

A 2014 Journal of Managed Care Pharmacy study reported that copay reductions for Medicare beneficiaries prescribed statins resulted in a 5.9% increase in adherence over 6 months compared to those paying standard copayments. A second 2014 JMCP study found a 4.9% increase in adherence among commercially insured individuals enrolled in a $0 copayment program for generic anti-diabetic and anti-hyperlipidemic medications. 

The basic premise of Value-Based Insurance Design (V-BID) is to align consumer incentives with value by reducing barriers to high-value health services and providers ("carrots"). When "carrots" are used in a clinically nuanced manner, V-BID improves health care quality and controls spending growth.  

Posted by Cristie Travis at 7:52 AM

From Our Blog

Say Hello

Please feel free to drop us a line via the button below. We try to respond to every email we receive.

Stay Connected

Join the MBGH community and keep up to date with issues concerning Memphis healthcare.

Facebook Twitter LinkedIn Feed